Zentalis Pharma - ZNTL Trailing Twelve Months Sales Growth

Public company logo of Zentalis Pharma (ZNTL)

Reviewing the annual sales growth over the trailing four quarters on GURU.Markets, we see that the -100.20 indicator reflects the state of the metric. High barriers in the form of patents and FDA control protect Zentalis Pharmaceuticals (ZNTL) from replication. The azenosertib inhibitor provides pricing power due to the inelastic demand of oncology patients. Currently, the company is actively developing next-generation combination therapies for the treatment of lung and ovarian cancers.

Zentalis Pharma (ZNTL) Sales Growth YoY (Last Twelve Months): for the period 02/11/2024 - 11/19/2026

zentalis.com (ZNTL) - metric breakdowns and financial figures

Analysis of all company metrics:Zentalis Pharmaceuticals Inc (ZNTL)
Product sample of Zentalis Pharmaceuticals

Selecting stocks with a high margin of safety requires an analysis of the issuer's actual business activity. This indicator measures the revenue growth rate over the last 12 months relative to the previous year, filtering out market noise. For Zentalis Pharmaceuticals (ZNTL), this parameter reflects the commercial demand for WEE1 inhibitors and the drug azazenisertib. The positive trend confirms the scaling of the biotech business. Evaluate the TTM year-over-year product sales dynamics to avoid buying at the peak.